Skip to content

Moderna MRNA Net Income

Net Income at other companies

Pfizer logo
PfizerPFE
$2.69B-9.4%
Novavax logo
NovavaxNVAX
-$9.49M-102%
ALN
Alnylam PharmaceuticalsALNY
$205.99M+1,229%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$185M-22.5%
Roivant Sciences logo
Roivant SciencesROIV
-$265.89M-257%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
-$320.62M-128%

Other financials

Income statement

See full
Revenue$389.0M+260%
Gross profit-$566.0M-3,244%
Operating income-$1.4B-32.2%
EPS (diluted)-$3.40-34.9%

Balance sheet

See full
Cash & equivalents$1.9B+17.4%
Total debt$1.3B+71.9%
Total equity$7.4B-26.4%
Total assets$11.5B-9.6%

Cash flow

See full
Operating cash flow-$630.0M+39.2%
CapEx$62.0M-47.0%
Free cash flow-$692.0M+40.0%

Valuation

See full
Market cap$27.09B+115%
Enterprise value$26.51B+120%
P/S12.2×+8.1×

Profitability

See full
Gross margin22.1%-32.0pp
Operating margin-153.3%+67.8pp
Net margin-143.6%+80.2pp
FCF margin-132.4%

Returns & leverage

See full
Return on equity-36.6%+11.9pp
Debt / equity0.2×+0.1×
Current ratio2.4×-1.8×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Moderna's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Moderna's net income?
Moderna (MRNA) reported net income of -$1.34B in Q1 2026.
How has Moderna's net income changed year-over-year?
Moderna's net income decreased by 38.3% year-over-year, from -$971M to -$1.34B.
What is the long-term trend for Moderna's net income?
Over 4 years (2021 to 2025), Moderna's net income has grown at a -30.7% compound annual growth rate (CAGR), from $12.2B to -$2.82B.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.